Along the same lines, recently published findings indicate that tissue (presumably low cytotoxic CD56bright NK cells) or blood NK-cell count (presumably a highly cytotoxic CD56dim NK-cell population) correlates with outcome in patients with FL and diffuse large B-cell lymphoma treated with R-CHOP or GA101-CHOP [20]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.